Trastuzumab deruxtecan in HER2-positive metastatic colorectal cancer: less is more?

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Access to Document

@article{2e06065911c94e2c86cf3db92a5367f1,

title = "Trastuzumab deruxtecan in HER2-positive metastatic colorectal cancer: less is more?",

author = "Roodhart, {Jeanine M.L.} and Miriam Koopman",

year = "2024",

month = sep,

doi = "10.1016/S1470-2045(24)00397-8",

language = "English",

volume = "25",

pages = "1104--1105",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "9",

}

TY - JOUR

T1 - Trastuzumab deruxtecan in HER2-positive metastatic colorectal cancer

T2 - less is more?

AU - Roodhart, Jeanine M.L.

AU - Koopman, Miriam

PY - 2024/9

Y1 - 2024/9

UR - http://www.scopus.com/inward/record.url?scp=85201905765&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(24)00397-8

DO - 10.1016/S1470-2045(24)00397-8

M3 - Comment/Letter to the editor

C2 - 39116901

AN - SCOPUS:85201905765

SN - 1470-2045

VL - 25

SP - 1104

EP - 1105

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 9

ER -